Product
FL-33 CAR T
1 clinical trial
1 indication
Clinical trial
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia:a Single-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-06-15